ASH 2021 | Real world analysis of brexucabtagene autoleucel in MCL
Yi Lin
• 11 Dec 2021
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares findings from a real world analysis of brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with mantle cell lymphoma (MCL). 93 patients who were treated from 14 different centers were included in the analysis, and a large majority of patients were not eligible for the ZUMA-2 trial (NCT02601313), due to a variety of factors. Patients who were ineligible for the trial were found to have comparable responses to patients eligible for the trial, highlighting the efficacy of brexucabtagene autoleucel. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
